Post-Treatment Persistent Erythrocytosis in Patients with Hodgkin Lymphoma: Molecular Mechanisms Underlying the Pathogenesis of Erythrocytosis
Cancers · 05.08.2026 · 18 (15) · 2504
DOI: 10.3390/cancers18152504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 05.08.2026. Verfasst von Derya Koyun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Ankara University School of Medicine, Ankara 06620, Turkey. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ankara University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
Background
Post-treatment erythrocytosis (PT-E+)—an increase in red blood cell counts after therapy—is an uncommon but reproducible finding in a subset of Hodgkin lymphoma (HL) survivors, and its biological basis remains undefined.
Methods
A targeted DNA sequencing panel of 33 genes was used at diagnosis and during follow-up in PT-E+ patients and HL controls who did not develop erythrocytosis (E−; those without increased red blood cells). Germline (inherited) and somatic (acquired) genetic variants were compared, and changes in variant frequency over time were assessed.
Results
PT-E+ patients had a unique molecular profile. They showed inherited variants in genes that regulate oxygen sensing and red blood cell production (EPAS1, EGLN3, HIF3A, PKLR, SH2B3, and RAB4B-EGLN2). Rare, acquired mutations affecting hypoxia, HIF, and EPO pathways (EGLN1/2/3, EPAS1, HIF1A/3A, VHL, EPO, and PKLR) were also found. These changes did not appear in E− controls, who instead had common clonal hematopoiesis mutations (DNMT3A, TET2, ASXL1, and JAK3). Most somatic variants in the hypoxia pathway in PT-E+ patients decreased or disappeared after treatment, which suggests these changes are temporary and influenced by the surrounding environment.
Conclusions
PT-E+ is biologically different from polycythemia vera and from idiopathic or JAK2-unmutated erythrocytosis. Both inherited risk and HL-related hypoxic or inflammatory stress are present. This supports a two-hit model, in which genetically primed red blood cell pathways respond strongly to disease-related triggers. These results suggest a new way to understand erythrocytosis after HL treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Department, Ankara University School of Medicine, Ankara 06620, Turkey.
- Hematology Department, Bitlis Eren University School of Medicine, Bitlis 13000, Turkey.
- Pathology Department, Ankara University School of Medicine, Ankara 06230, Turkey.
- Hematology Department, Koç University School of Medicine, Istanbul 34010, Turkey.
- Medical Genetics Department, Ankara University School of Medicine, Ankara 06230, Turkey.
Förderung
- Ankara University Scientific Research Projects Coordination Unit
Zitieren
APA
Koyun, D., Yüksel, S., Civriz Bozdağ, S., Tuncalı, T., Kuzu, I., & Özcan, M. (2026). Post-Treatment Persistent Erythrocytosis in Patients with Hodgkin Lymphoma: Molecular Mechanisms Underlying the Pathogenesis of Erythrocytosis. Cancers, 18(15), 2504. https://doi.org/10.3390/cancers18152504
Vancouver
Koyun D, Yüksel S, Civriz Bozdağ S, Tuncalı T, Kuzu I, Özcan M. Post-Treatment Persistent Erythrocytosis in Patients with Hodgkin Lymphoma: Molecular Mechanisms Underlying the Pathogenesis of Erythrocytosis. Cancers. 2026;18(15):2504. doi:10.3390/cancers18152504
BibTeX
@article{Koyun2026,
author = {Koyun, Derya and Yüksel, Seher and Civriz Bozdağ, Sinem and Tuncalı, Timur and Kuzu, Işınsu and Özcan, Muhit},
title = {Post-Treatment Persistent Erythrocytosis in Patients with Hodgkin Lymphoma: Molecular Mechanisms Underlying the Pathogenesis of Erythrocytosis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2504},
doi = {10.3390/cancers18152504}
}
EUVIMED